Autolus Therapeutics (NASDAQ:AUTL) Stock Rating Upgraded by Wall Street Zen

Key Points

• Wall Street Zen upgraded Autolus Therapeutics from “sell” to “hold,” while the broader analyst consensus remains “Moderate Buy” with a $10.00 price target.
• Autolus reported quarterly revenue of $45.69 million and an adjusted loss of $0.15 per share, beating analyst estimates for both revenue and EPS.
• Institutional investors own approximately 72.83% of the company, with several major funds increasing their positions; the stock recently traded at $2.15, within its 12-month range of $1.17 to $2.43.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a report released on Sunday.

Other analysts have also issued reports about the company. Jefferies Financial Group upgraded Autolus Therapeutics to a "strong-buy" rating in a research note on Monday, April 20th. HC Wainwright reaffirmed a "buy" rating and set a $10.00 target price on shares of Autolus Therapeutics in a report on Monday, August 3rd. Finally, Weiss Ratings cut Autolus Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday, July 31st. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Autolus Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $10.00.

Autolus Therapeutics Stock Performance

NASDAQ AUTL opened at $2.15 on Friday. The firm has a market cap of $572.24 million, a P/E ratio of -2.03 and a beta of 2.07. The company has a quick ratio of 5.28, a current ratio of 4.89 and a debt-to-equity ratio of 1.04. The company's 50 day moving average is $1.64 and its 200-day moving average is $1.57. Autolus Therapeutics has a 12-month low of $1.17 and a 12-month high of $2.43.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.06. Autolus Therapeutics had a negative net margin of 238.66% and a negative return on equity of 178.66%. The company had revenue of $45.69 million during the quarter, compared to the consensus estimate of $38.56 million. Sell-side analysts predict that Autolus Therapeutics will post -0.8 earnings per share for the current year.

Institutional Investors Weigh In On Autolus Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Syncona Portfolio Ltd bought a new stake in Autolus Therapeutics during the second quarter valued at $26,625,152,000. Schroder Investment Management Group raised its holdings in shares of Autolus Therapeutics by 133.7% in the 3rd quarter. Schroder Investment Management Group now owns 8,433,253 shares of the company's stock valued at $13,409,000 after acquiring an additional 4,824,763 shares in the last quarter. Mak Capital One LLC raised its holdings in shares of Autolus Therapeutics by 15.3% in the 4th quarter. Mak Capital One LLC now owns 30,005,343 shares of the company's stock valued at $59,711,000 after acquiring an additional 3,987,727 shares in the last quarter. Armistice Capital LLC raised its holdings in shares of Autolus Therapeutics by 30.0% in the 3rd quarter. Armistice Capital LLC now owns 15,600,000 shares of the company's stock valued at $25,428,000 after acquiring an additional 3,600,000 shares in the last quarter. Finally, Bank of America Corp DE boosted its position in shares of Autolus Therapeutics by 108.1% during the 3rd quarter. Bank of America Corp DE now owns 2,029,593 shares of the company's stock valued at $3,308,000 after acquiring an additional 1,054,458 shares during the last quarter. Hedge funds and other institutional investors own 72.83% of the company's stock.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company's leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source